Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer

被引：0
作者：
Borrego, M. Ruiz
De la Haba, J.
Morales, S.
Ramos, M.
Velasco, A.
Mendez, M.
Carabantes, F.
Barnadas, A.
Garcia, M.
Moreno, J. A.
机构：
[1] Virgin Rocio Hosp, Dept Oncol, Seville, Spain
[2] Reina Sofia Hosp, Dept Oncol, Cordoba, Spain
[3] Arnau Vilanova Hosp, Lleida, Spain
[4] Oncol Ctr Galicia, Dept Oncol, La Coruna, Spain
[5] La Princesa Hosp, Dept Oncol, Madrid, Spain
[6] Mostoles Hosp, Dept Oncol, Mostoles, Spain
[7] Carlos Haya Hosp, Dept Oncol, Malaga, Spain
[8] Hosp Germans Trias & Pujol, Dept Oncol, Badalona, Spain
[9] Ciudad Real Hosp, Dept Oncol, Ciudad Real, Spain
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
[41]   Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer [J].
Chen, Xue-Lian ;
Du, Feng ;
Hong, Ruo-Xi ;
Wang, Jia-Yu ;
Luo, Yang ;
Li, Qing ;
Fan, Ying ;
Xu, Bing-He .
CHINESE JOURNAL OF CANCER, 2016, 35
[42]   Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer [J].
Bian Li ;
Xu Feng-Rui ;
Jiang Ze-Fei .
中华医学杂志英文版, 2020, 133 (19) :2338-2345
[43]   Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer [J].
Bian, Li ;
Xu, Feng-Rui ;
Jiang, Ze-Fei .
CHINESE MEDICAL JOURNAL, 2020, 133 (19) :2338-2345
[44]   When to Combine Endocrine Therapy With a New Agent for Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women [J].
Seidman, Andrew D. .
ONCOLOGY-NEW YORK, 2016, 30 (03) :224-228
[45]   Capecitabine Maintenance Therapy after First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer [J].
Yan LiJing Li Ming LuXicheng WangLin Shen Key Laboratory of Carcinogenesis and Translational ResearchMinistry of Education ;
Department of GI OncologyPeking University School of OncologyBeijing Cancer Hospital InstituteBeijing China .
Chinese Journal of Cancer Research, 2010, 22 (03) :181-185
[46]   Capecitabine Maintenance Therapy after First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer [J].
Li, Yan ;
Li, Jing ;
Lu, Ming ;
Wang, Xi-cheng ;
Shen, Lin .
CHINESE JOURNAL OF CANCER RESEARCH, 2010, 22 (03) :181-185
[47]   LapatinibIn Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer [J].
Monique P. Curran .
Drugs, 2010, 70 :1411-1422
[48]   Lapatinib In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer [J].
Curran, Monique P. .
DRUGS, 2010, 70 (11) :1411-1422
[49]   Patterns of progression in oligometastatic hormone receptor positive breast cancer after first-line systemic treatment at the metastatic stage [J].
Lacaze, Jean Louis ;
De Maio, Eleonora ;
Chaltiel, Leonor ;
Cabarrou, Bastien ;
Mounat, Thibaut Cassou ;
Chira, Ciprian ;
Glemarec, Gauthier ;
Massabeau, Carole ;
Nicolai, Vincent ;
Selmes, Gabrielle .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50]   Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases [J].
El-Saghir, Nagi S. ;
El-Hajj, Ihab I. ;
Makarem, Jawad A. ;
Otrock, Zaher K. .
ANTI-CANCER DRUGS, 2006, 17 (08) :999-1002
12345